Trinity Biotech Surges Again

Investors follow through on Monday's rally triggered by FDA approval of HIV testing device.
Publish date:

Shares in

Trinity Biotech

(TRIB) - Get Report

surged for a second day Tuesday, after the company's announcement Monday that it had received Food and Drug Administration approval to market its low-cost HIV test in the U.S.

Recently, shares were up another $1.02, or 20%, to $6.16, following a 57% gain Monday.

The company said its Uni-Gold Recombigen test, which is already in use in South Africa,yields results in 10 minutes.

The company also said its product is the only one capable of detecting antibodies to HIV in human blood serum, plasma and whole blood.

The Dublin, Ireland-based company specializes in test kits for the detection of diseases and will sell the testing device directly to hospitals and physicians.